Search

Your search keyword '"Yavas, G."' showing total 211 results
Start Over Author "Yavas, G."
211 results on '"Yavas, G."'

7. The Treatment Outcomes of Oligometastatic Colorectal Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Multi-Institutional Analysis TROD 02-008

Author

Guler, O.C., primary, Hurmuz, P., additional, Atalar, B., additional, Guney, Y. Yukselen, additional, Saglam, E.K., additional, Akyurek, S., additional, Bolukbasi, Y., additional, Güral, Z., additional, Tugrul, F., additional, Korcum, A.F., additional, Sen, C.A., additional, Yildirim, B. Akkus, additional, Oksuz, D.C., additional, Celik, O. Karakoyun, additional, Kurt, M., additional, Guzeloz, Z., additional, Yavas, G., additional, Ozyigit, G., additional, Aksu, M.G., additional, and Onal, C., additional

Published
2022
Full Text
View/download PDF

12. The Treatment Outcomes of Patients with Cervical Esophageal Carcinoma Undergoing Definitive Chemoradiotherapy: A Multi-Institutional Analysis TROD 01-005

Author

Guler, O.C., primary, Oymak, E., additional, Yazici, G., additional, Akagunduz, O. Ozkaya, additional, Cetinayak, O., additional, Erpolat, P., additional, Aksoy, A., additional, Duzova, M., additional, Yildirim, B. Akkus, additional, Kurt, M., additional, Canyılmaz, E., additional, Akyurek, S., additional, Atalar, B., additional, Yavas, G., additional, Oksuz, D.C., additional, Saglam, E.K., additional, Celik, O. Karakoyun, additional, Cengiz, M., additional, and Onal, C., additional

Published
2022
Full Text
View/download PDF

20. Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing

Author

Xiao, W., Ren, L., Chen, Z., Fang, L.T., Zhao, Y., Lack, J., Guan, M., Zhu, B., Jaeger, E., Kerrigan, L., Blomquist, T.M., Hung, T., Sultan, M., Idler, K., Lu, C., Scherer, A., Kusko, R., Moos, M., Xiao, C., Sherry, S.T., Abaan, O.D., Chen, W., Chen, X., Nordlund, J., Liljedahl, U., Maestro, R., Polano, M., Drabek, J., Vojta, P., Kõks, S., Reimann, E., Madala, B.S., Mercer, T., Miller, C., Jacob, H., Truong, T., Moshrefi, A., Natarajan, A., Granat, A., Schroth, G.P., Kalamegham, R., Peters, E., Petitjean, V., Walton, A., Shen, T-W, Talsania, K., Vera, C.J., Langenbach, K., de Mars, M., Hipp, J.A., Willey, J.C., Wang, J., Shetty, J., Kriga, Y., Raziuddin, A., Tran, B., Zheng, Y., Yu, Y., Cam, M., Jailwala, P., Nguyen, C., Meerzaman, D., Chen, Q., Yan, C., Ernest, B., Mehra, U., Jensen, R.V., Jones, W., Li, J-L, Papas, B.N., Pirooznia, M., Chen, Y-C, Seifuddin, F., Li, Z., Liu, X., Resch, W., Wu, L., Yavas, G., Miles, C., Ning, B., Tong, W., Mason, C.E., Donaldson, E., Lababidi, S., Staudt, L.M., Tezak, Z., Hong, H., Wang, C., Shi, L., Xiao, W., Ren, L., Chen, Z., Fang, L.T., Zhao, Y., Lack, J., Guan, M., Zhu, B., Jaeger, E., Kerrigan, L., Blomquist, T.M., Hung, T., Sultan, M., Idler, K., Lu, C., Scherer, A., Kusko, R., Moos, M., Xiao, C., Sherry, S.T., Abaan, O.D., Chen, W., Chen, X., Nordlund, J., Liljedahl, U., Maestro, R., Polano, M., Drabek, J., Vojta, P., Kõks, S., Reimann, E., Madala, B.S., Mercer, T., Miller, C., Jacob, H., Truong, T., Moshrefi, A., Natarajan, A., Granat, A., Schroth, G.P., Kalamegham, R., Peters, E., Petitjean, V., Walton, A., Shen, T-W, Talsania, K., Vera, C.J., Langenbach, K., de Mars, M., Hipp, J.A., Willey, J.C., Wang, J., Shetty, J., Kriga, Y., Raziuddin, A., Tran, B., Zheng, Y., Yu, Y., Cam, M., Jailwala, P., Nguyen, C., Meerzaman, D., Chen, Q., Yan, C., Ernest, B., Mehra, U., Jensen, R.V., Jones, W., Li, J-L, Papas, B.N., Pirooznia, M., Chen, Y-C, Seifuddin, F., Li, Z., Liu, X., Resch, W., Wu, L., Yavas, G., Miles, C., Ning, B., Tong, W., Mason, C.E., Donaldson, E., Lababidi, S., Staudt, L.M., Tezak, Z., Hong, H., Wang, C., and Shi, L.

Abstract

Clinical applications of precision oncology require accurate tests that can distinguish true cancer-specific mutations from errors introduced at each step of next-generation sequencing (NGS). To date, no bulk sequencing study has addressed the effects of cross-site reproducibility, nor the biological, technical and computational factors that influence variant identification. Here we report a systematic interrogation of somatic mutations in paired tumor–normal cell lines to identify factors affecting detection reproducibility and accuracy at six different centers. Using whole-genome sequencing (WGS) and whole-exome sequencing (WES), we evaluated the reproducibility of different sample types with varying input amount and tumor purity, and multiple library construction protocols, followed by processing with nine bioinformatics pipelines. We found that read coverage and callers affected both WGS and WES reproducibility, but WES performance was influenced by insert fragment size, genomic copy content and the global imbalance score (GIV; G > T/C > A). Finally, taking into account library preparation protocol, tumor content, read coverage and bioinformatics processes concomitantly, we recommend actionable practices to improve the reproducibility and accuracy of NGS experiments for cancer mutation detection.

Published
2021

22. The impact of spironolactone on the lung injury induced by concomitant trastuzumab and thoracic radiotherapy

Author

Yavas, G., Yavas, C., Celik, E., Sen, E., Ata, O., Afsar, R. E., Selçuk Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Yavas, G., Yavas, C., Celik, E., Sen, E., Ata, O., and Afsar, R. E.

Subjects
spironolactone, pulmonary fibrosis, Trastuzumab, Aldosterone, radiotherapy
Abstract

WOS: 000464529800009, Background: To evaluate impact of spironolactone (S) on pulmonary toxicity of concomitant use of thoracic radiotherapy (RT) and trastuzumab (T). Materials and Methods: Eighty rats were divided into eight groups: group (G) 1 was control group; G2, G3 and G4 were RT, S and T groups; G5, G6, G7 and G8 were RT+T, T+S, RT+S and RT+T+S groups respectively. Rats were sacrificed at 6 hour, 21 and 100 day after RT and lung samples were retrieved. Results: By 100th days of RT inflammation score, lung fibrosis score and TGF- expression were significantly different within study groups (p values were 0.002, 0.001 and 0.043 respectively). Inflammation score of G8 was significantly lower than inflammation scores of G2 and G5 (p values: G2-G8=0.004, and G5-G8=0.022). Inflammation score of G2 was significantly higher than G7 (p=0.028). There were significant differences regarding to fibrosis scores between G2-G8 (p=0.015), G2-G7 (p=0.017) and G5-G8 (p=0.011). TGF-beta expression was higher in both G2 and G5 when compared to G8 (p = 0.038). Conclusion: Our results suggested that S is an effective treatment option for improving radiation-induced pulmonary fibrosis. These findings should be clarified with further preclinical and clinical studies., Selcuk UniversitySelcuk University, This work was supported by Selcuk University. There is no role of study sponsors in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript and in the decision to submit the manuscript for publication.

Published
2019

42. The use of concurrent hormonotherapy and radiotherapy does not deteriorate radiation-induced cardiac toxicity.

Author

Yavas, C., Yavas, G., Toy, H., and Ata, O.

Subjects
*RADIOTHERAPY, *ELECTROTHERAPEUTICS, *HOSPITAL radiological services, *MEDICAL electronics, *MEDICAL radiology
Abstract

Postmenopausal patients with breast cancer have two options for adjuvant endocrine therapy, tamoxifen and aromatase inhibitors (AIs) as well as radiotherapy (RT) and chemotherapy. However, there is limited data regarding the optimal sequencing of RT and tamoxifen/AIs. Thus, we aimed to evaluate the effects of tamoxifen and AIs on radiation-induced cardiotoxicity. Eighty ovariectomized rats were divided into eight groups (G). G1 was defined as a control group; G2, G3, G4, and G5 were RT, tamoxifen, anastrozle, and letrozole groups, respectively; G6, G7, and G8 were RT plus tamoxifen, anastrozle, and letrozole groups, respectively. Drugs were started 1 week before RT and continued until the animals were killed 16 weeks after RT. The heart tissues were then dissected and examined with light microscopy to determine endocardial thickness and cardiac fibrosis. The endocardial thickness scores of both RT alone and the tamoxifen groups as well as the cardiac fibrosis score of RT alone were higher than that the control group (p < 0.05 for all). There was no difference in the endocardial thickness and cardiac fibrosis scores of the RT-only group and the RT plus hormonotherapy groups (p > 0.05 for all). Concurrent administration of RT and hormonal therapy with either tamoxifen or AIs did not further amplify radiation-induced cardiac toxicity. This issue warrants further study. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

43. Amelioration of radiation-induced lung injury by halofuginone: An experimental study in Wistar-Albino rats.

Author

Calik, M., Yavas, G., Calik, S. G., Yavas, C., Celik, Z. E., Sargon, M. F., and Esme, H.

Subjects
*LUNG injuries, *PHYSIOLOGICAL effects of radiation, *ANTIPROTOZOAL agents, *LABORATORY rats, *PNEUMONIA, *PULMONARY fibrosis
Abstract

To evaluate effects of halofuginone (H) on radiation-induced lung injury (RILI), 60 rats were divided into six groups: Group (G) 1 control, G2 radiotherapy (RT) only, G3 and G4 2. 5 and 5 μg H and G5 and G6 RT + 2.5 and 5 μg H groups, respectively. A single dose of 12 Gy RT was given to both lungs. H was applied intraperitoneally with daily doses, until animals were killed at 6 and 16 weeks after RT. At 6th and 16th weeks of RT, five rats from each group were killed. Lung tissues were dissected for light and electron microscopy. Chronic inflammation, fibrosis and transforming growth factor-beta (TGF)-β scores of all study groups were significantly different at 6th and 16th week (p < 0.001). Chronic inflammation, fibrosis and TGF-β scores of G2 were higher than G5 and G6 at 6th and 16th weeks of RT. At 16th week, fibrosis and TGF-β scores of G5 were higher than G6 (p = 0.040 and 0.028, respectively). Electron microscopical findings also supported these results. Therefore, H may ameliorate RILI. The effect of the H was more prominent at higher dose and after long-term follow-up. These findings should be clarified with further studies. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

46. Clustering mobile trajectories for resource allocation in mobile environments

Author

Katsaros, D., Nanopoulos, A., Karakaya, M., Yavas, G., Ulusoy, Özgür, Manolopoulos, Y., and Ulusoy, Özgür

Subjects
Paging Area, Location Prediction, Baseline Algorithm, Mobile Client, Resource Allocation
Abstract

The recent developments in computer and communication technologies gave rise to Personal Communication Systems. Due to the nature of the PCS, the bandwidth allocation problem arises, which is based on the notion of bandwidth-on-demand. We deal with the problem of how to predict the position of a mobile client. We propose a new algorithm, called DCP, to discover user mobility patterns from collections of recorded mobile trajectories and use them for the prediction of movements and dynamic allocation of resources. The performance of the proposed algorithm is examined against two baseline algorithms. The simulation results illustrate that the proposed algorithm achieves recall that is comparable to that of the baseline algorithms and substantial improvement in precision. This improvement guarantees very good predictions for resource allocation with the advantage of very low resource consumption. © Springer-Verlag Berlin Heidelberg 2003.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results